Literature DB >> 1509628

Radioisotopic evaluation of renal transplants.

E K Dunn1.   

Abstract

Owing to the noninvasive nature, ready availability, and efficacy, radionuclide studies remain widely utilized following renal transplantation for monitoring changes in the functional status and detection of detrimental complications of the grafted kidney. Whereas surgical complications, including vascular occlusion, urine extravasation, drainage obstruction, hematoma, or lymphocele formation, can often be detected effectively, specification of other underlying causes of deterioration of parenchymal function, including acute tubular necrosis (ATN), various types of rejection, and cyclosporine A nephrotoxicity (CyA-NT), frequently cannot be derived independently from the findings of a study without clinical correlation. Besides imaging, plotting of renogram or time/activity curves, numerous quantitative methods have been introduced to provide objective measurements of the blood flow, as well as to gauge the capability of concentration and excretion of the transplanted kidneys. However, the findings whether qualitative or quantitative all have overlapping zones. There is no abnormal image, graphic, or numeric index absolutely specific for any of the possible posttransplant renal parenchymal complications. The differentiation of such conditions may best be achieved through chronologic association of the sequential changes, with or without quantification, detected in serial studies with the clinical presentation and findings.

Entities:  

Mesh:

Year:  1992        PMID: 1509628     DOI: 10.1007/bf02926912

Source DB:  PubMed          Journal:  Urol Radiol        ISSN: 0171-1091


  1 in total

1.  Quantified power Doppler as a predictor of delayed graft function after renal transplantation.

Authors:  Mariana Moraes Contti; Paula Dalsoglio Garcia; Cristiane Akemi Kojima; Hong Si Nga; Maria Fernanda Cordeiro de Carvalho; Luis Gustavo Modelli de Andrade
Journal:  Int Urol Nephrol       Date:  2014-12-14       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.